Clinical Trials for: oxaliplatin
Oxaliplatin in Treating Patients With Metastatic Breast Cancer
Status: Recruiting Condition: Stage IV Breast Cancer
Study of S-1 and Oxaliplatin (SOX) Versus Capecitabine and Oxaliplatin (COX) in Patients With Advanced Colorectal Cancer
Status: Completed Condition: Colorectal Cancer
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
Status: Terminated Condition: Adenocarcinoma of the Pancreas; Adenocarcinoma of the Stomach; BRCA1 Mutation Carrier; BRCA2 Mutation Carrier; Ovarian Mucinous Cystadenocarcinoma; Recurrent Breast Cancer; Recurrent Colon Cancer; Recurrent Gastric Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Pancreatic Cancer; Recurrent Rectal Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Stage IV Colon Cancer; Stage IV Gastric Cancer; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Pancreatic Cancer; Stage IV Rectal Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL
Status: Completed Condition: Leukemia
Combination of CPT-11 and LoHP vs Combination of 5-FU, Leucovorin and LoHP as 1st Line Treatment in Gastric Patients
Status: Completed Condition: Gastric Cancer
Phase III Study to Compare Perioperative Chemotherapy of Oxaliplatin Combined With S-1(SOX) Versus SOX or Oxaliplatin With Capecitabine (XELOX) as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma With D2 Dissection
Status: Recruiting Condition: Advanced Gastric Carcinoma
Courtesy of ClinicalTrials.org
See more clinical trials for this drug
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||Type||RLD||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Patented / Exclusive Use|
|INJECTABLE;IV (INFUSION)||022160||Aug 7, 2009||RX||Yes||<disabled>|
Sun Pharma Global
|INJECTABLE;IV (INFUSION)||202922||Apr 8, 2014||RX||No||<disabled>|
Sun Pharma Global
|INJECTABLE;IV (INFUSION)||078818||Aug 7, 2009||RX||Yes||<disabled>|
|INJECTABLE;IV (INFUSION)||090849||Apr 28, 2011||DISCN||No||<disabled>|
|This preview shows a limited data set|
Complete access is available with a Subscription
Export unavailable in trial.
Subscribe for complete access.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639